Zhuhai Federal Biomedical Co., Ltd.

This study used semaglutide injection developed by Zhuhai United Biopharmaceutical Co., Ltd. (hereinafter referred to as "United Bio") and semaglutide injection developed and produced by Novo Nordisk to treat obese patients for 44 weeks, and compared the changes in body weight, waist circumference, etc. from baseline before and after treatment between the two groups; at the same time, the incidence of gastrointestinal events, hypoglycemia events and other related safety indicators between the two groups were compared. The main purpose is to evaluate the efficacy and safety of semaglutide injection developed by United Bio in the treatment of obese patients.

To study the efficacy and safety of degludec insulin liraglutide injection developed by United Biotechnology in patients with type 2 diabetes.

The primary objective is to investigate the pharmacokinetic characteristics of degludec insulin liraglutide injection and to compare the pharmacokinetic similarity of a single subcutaneous injection of degludec insulin liraglutide (test preparation) with the original drug "NovoElix®" (reference preparation) in healthy Chinese adult subjects. The secondary objective is to evaluate the safety of degludec insulin liraglutide injection and preliminarily evaluate its immunogenicity.